Claris Lifesciences Ltd cmp (242.00)

                             Claris Lifesciences Ltd

 

Claris Injectables Limited, a wholly-owned subsidiary of Claris Lifesciences Limited - collectively “Claris”, is a sterile injectables pharmaceutical company with a market presence across the world. Claris manufactures and/or markets products across multiple delivery systems, markets, and therapeutic segments.

 A significant majority of these products are generic drugs that are capable of being directly injected into the human body; our products are predominantly used in the treatment of critical illnesses. Our customer base primarily includes government and private hospitals, aid agencies, and nursing homes.

 products range across various therapeutic segments, including anesthesia, blood products, anti-infectives, and plasma volume expanders. With emphasis on quality, technology, and innovation, we offer a range of niche technology-driven injectable products across delivery systems such as glass bottles, vials & ampoules, and non-PVC/PVC bags.

company  have three manufacturing facilities at a campus located in Ahmedabad, India. Claris' sterile injectables facilities have been approved by regulatory authorities including US FDA, MHRA (UK), TGA (Australia), and GCC FDCA. Our manufacturing capabilities have received several awards from prestigious institutions like IDMA (Indian Drug Manufacturers' Association) and Frost & Sullivan India Manufacturing Excellence Award.

 capabilities and experience span across all business verticals in the specialty injectables industry. We have a trained workforce across business functions, such as product development, regulatory affairs for obtaining product registrations, manufacturing, and sales & marketing.

look at last 4 quarters financial performance

Narration	Mar-14	Jun-14	Sep-14	Dec-14
Quarter	4th Qtr	1st Qtr	2nd Qtr	3rd Qtr
Sales	136.82	156.35	166.05	182.61
Operating Profit	19	28.39	38.74	46.57
Other Income	19.11	13.05	12.79	26.78
EBIDT	38.11	41.44	51.53	73.35
Interest	8.74	9.09	8.61	11.36
Depreciation	10.18	10.32	10.67	8.96
Tax	3.79	5.96	9.87	-37.27
Net profit	13.34	15.48	20.37	89.85
Adjusted EPS in	2.09	2.84	3.73	16.46

This year company changed year end from  Dec to Mar. so they publish 15months results

  when injectable business is valued at 3000 cr mcap is 1350 cr and it has 600 cr cash

so one can expect good return in this company